WeVote
Log In

Bill

Bill

S 3060

Relates to the construction of pipe lines

2025 Regular Session Introduced by Leroy Comrie

Requires NJ health plans to cover annual prostate cancer screening with no cost-sharing for men 40–75, including DRE, PSA and follow-up imaging as needed.

REFERRED TO CORPORATIONS, AUTHORITIES AND COMMISSIONS
0
WeVote Research Nonpartisan
Bill Summary · S 3060

Summary — S 3060 (Introduced Version)

Bill number: S 3060
Short title (file header): Relates to the construction of pipe lines — (See Note below)
Introduced: October 28, 2025
Status: Referred to Corporations, Authorities and Commissions (also previously read and referred to Appropriations; earlier referrals to Commerce Committee)
Primary sponsors: Senator John Kennedy; Senators Troy Singleton and Leroy Comrie
Related/companion bills: S3079; HR5660; HR5401; S3002; A1841; prior-session bills S7979, S5139, S8883, S3765, S1622

Overview / Purpose

S 3060 would require specified health insurance contracts and policies in New Jersey to cover annual prostate cancer screening and related follow-up testing. The bill amends P.L.1996, c.125 and several statutory provisions that govern health service, hospital service, and medical service corporation contracts and group health insurance policies to (1) define prostate cancer screening more broadly and (2) eliminate cost‑sharing for certain age groups.

Key provisions

  • Amends multiple statutes (including C.17:48E‑35.13 and related sections: C.17:48‑6p; C.17:48A‑7n; C.17B:27‑46.1o) to require that contracts/policies “provide benefits … for expenses incurred in conducting an annual prostate cancer screening.”
  • Defines “prostate cancer screening” to include:
    • Digital rectal exam (DRE)
    • Prostate‑specific antigen (PSA) test and associated laboratory work
    • Subsequent follow‑up testing ordered by a provider, including urine analysis, serum biomarkers, and medical imaging (including MRI)
  • Requires that these benefits be provided to the same extent as for any other medical condition under the contract or policy.
  • Prohibits any deductible, coinsurance, copayment, or other cost‑sharing for men aged 40 through 75.
  • Applies where the issuer (health service/hospital/medical service corporation or health insurer) has reserved the right to change the premium (i.e., to applicable contracts/policies).

Who is affected

  • Insurers and health, hospital, and medical service corporations issuing contracts or group policies in New Jersey that reserve premium‑change rights.
  • Covered individuals: men eligible for screening under plans subject to the statute, with explicit no cost‑sharing for those aged 40–75.
  • Health care providers who perform screenings and follow‑up testing.

Procedural / timeline notes

  • Introduced Oct 28, 2025; read twice and referred to Appropriations; currently listed as referred to Corporations, Authorities and Commissions. Some records show earlier referrals (Commerce Committee) — multiple referrals appear in the history.
  • This is the introduced version; if advanced, implementing regulations or insurer plan changes would follow normal administrative and rate‑filing processes.

Potential impacts

  • Likely increases utilization of prostate cancer screening and related diagnostic services among insured men, particularly ages 40–75, by removing cost barriers.
  • Could increase insurers’ short‑term claims costs; potential downstream clinical benefits from earlier detection could affect long‑term costs and outcomes.
  • Expands the defined set of covered screening modalities (e.g., MRI, serum biomarkers), potentially increasing use of higher‑cost diagnostic tools.

Notes / Observations

  • The bill text provided focuses entirely on insurance coverage for prostate cancer screening, but the bill header/title in the file (“Relates to the construction of pipe lines”) appears inconsistent with the content; this likely reflects a clerical or filing discrepancy.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.